 -- EXPAREL is the first and only FDA-approved long-acting local analgesic for children aged six and over -- Conference call tomorrow at 8:30 a.m. ET -- PARSIPPANY, N.J., March 22, 2021 GLOBE NEWSWIRE -- Pacira BioSciences, Inc. Nasdaq: PCRX, the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration FDA has approved the submission of its supplemental new drug application sNDA seeking expansion of the EXPAREL label to include use in patients 6 years of age and older for single-dose infiltration to produce postsurgical local analgesia. With this approval, EXPAREL is the first and only FDA approved long-acting local analgesic for the pediatric population as young as age six. 